NCT00681551已完成3 期
Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 45
- 主要终点
- Diagnostic ability
研究概览
简要总结
To verify the number of metastatic brain tumors detected in contrast-enhanced MRI, which is the primary variable, increases after an additional dose of Magnevist (SH L 451A) comparing images after an initial dose (0.1 mmol/kg) with those after an additional dose (0.1 mmol/kg, a total dose of 0.2 mmol/kg) intra-individually in patients with metastatic brain tumors. Safety was also to be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are confirmed to have 1-5 metastatic brain tumor by the latest contrast-enhanced cerebral CT or contrast-enhanced cerebral MRI, and the lesion(s) have not been treated by surgery or by stereotactic radiosurgery.
排除标准
- •Patients who are scheduled to receive another contrast medium for MRI (except for oral agents) or iodine contrast medium (except for oral agents), or to undergo surgical procedures during the period from the day before administration of Magnevist (SH L 451A) to examination of safety on the following day.
- •Patients who underwent or are scheduled to undergo radiotherapy during the period from 14 days before administration of Magnevist (SH L 451A) to examination of safety on the following day.
- •Patients who were treated or are scheduled to be treated with anti-cancer agents (except for treatment only by the oral agents of the fixed dose continuously from 28 days or more before administration of Magnevist (SH L 451A)) during the period from 28 days before administration of Magnevist (SH L 451A) to examination of safety on the following day.
研究组 & 干预措施
Arm 1
Active Comparator
干预措施: Magnevist (SH L 451A) (Drug)
Arm 2
Experimental
干预措施: Magnevist (SH L 451A) (Drug)
结局指标
主要结局
Diagnostic ability
时间窗: MRI image in blinded read
次要结局
- Visibility(MRI image in blinded read)
- Diagnostic confidence(MRI image in blinded read)
研究者
相似试验
终止
2 期
CEST- Glucose Enhanced MRI for Metastatic Brain TumoursBrain Neoplasms, MalignantMetastasisNCT02796729British Columbia Cancer Agency3
已完成
不适用
Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial TumorsBrain NeoplasmsAdult Brain TumorNCT03525080Center Eugene Marquis16
招募中
不适用
MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast CancerBreast CancerNCT06247449Sunnybrook Health Sciences Centre100
已完成
不适用
Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)Brain TumorsNCT00724191University of Michigan88
已完成
不适用
Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade GliomasRecurrent High Grade GliomasNCT00942760Dartmouth-Hitchcock Medical Center12